Caredx announces landmark data in ai-powered transplant diagnostics showcased in over 40 abstracts and 16 oral presentations at the 2025 world transplant congress

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna), — the transplant company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the presentation of several high-impact studies and digital health innovations by independent research teams at the 2025 world transplant congress (wtc), demonstrating advances in artificial.
CDNA Ratings Summary
CDNA Quant Ranking